Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)

NCT00613106 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00613106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00613106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2007
Completion date
October 31, 2008
Enrollment
179 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic low back pain, chronic regional pain syndrome, chronic soft tissue pain, osteoarthritis, rheumatoid arthritis